Semaglutide is a synthetic version of GLP-1, a hormone your gut releases after you eat. GLP-1 tells your brain you're full, slows digestion, and signals your pancreas to release insulin. Semaglutide does the same thing — but instead of disappearing from your bloodstream in minutes like the natural version, it sticks around for about a week. That sustained signal is what makes it so effective for weight loss and blood sugar control.
The appetite suppression is the effect people notice most. Within days of starting, food becomes less appealing, portions naturally shrink, and the constant background noise of hunger that many people live with simply quiets down. This isn't willpower — it's a chemical shift in how your brain processes food signals. The result is a calorie deficit that doesn't require constant effort to maintain.
Semaglutide is the active ingredient in Ozempic (approved for type 2 diabetes in 2017) and Wegovy (approved specifically for obesity in 2021). The clinical trial data is among the strongest ever seen for a weight loss drug. In the STEP trials, people lost an average of 15% of their body weight over 68 weeks — results that had never been achieved with a medication before.
Outside of clinical prescriptions, semaglutide is widely used in wellness clinics and the biohacking community, often compounded and sold at a fraction of the brand-name price. The results translate well outside trials, though side effects — particularly nausea early on — are real and need to be managed.
For educational and research purposes only. Never use any peptide or substance based on information found here — always consult a licensed healthcare professional before making any medical or health-related decision.
Semaglutide was developed by Novo Nordisk and has one of the most extensive clinical trial programs of any drug in recent history. The SUSTAIN trials established its efficacy for type 2 diabetes, and the STEP trials established it for obesity. STEP 1 showed 14.9% average weight loss versus 2.4% for placebo over 68 weeks — a result that reshaped how obesity is treated medically.
The cardiovascular data is also significant. The LEADER trial and subsequent SELECT trial showed semaglutide reduces the risk of major cardiovascular events in high-risk patients. This makes it unusual among weight loss treatments — it doesn't just change the number on the scale, it improves hard clinical outcomes.
The mechanism is well understood. Semaglutide binds to GLP-1 receptors in the brain's hypothalamus, reducing food intake by affecting the reward and satiety pathways simultaneously. It also slows gastric emptying, which extends the feeling of fullness after eating.
Long-term use data is still accumulating, but five-year follow-up data from diabetes trials shows sustained glycemic control and consistent weight maintenance. The main open question is what happens to muscle mass and metabolic rate with very long-term use, which is being studied actively.
No reviews yet. Be the first.